3-(2-Benzyl-4-chlorophenyl)prop-2-enenitrile | 81992-92-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-Benzyl-4-chlorophenyl)prop-2-enenitrile
• CAS: 81992-92-9
• 化学式: C₁₆H₁₂ClN
• 分子量: 253.72
• InChiKey: ZQDBTVYWVDEAOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(2-Benzyl-4-chlorophenyl)prop-2-enenitrile 、 二氯甲烷 、 溶剂黄146 、 乙醇 在 chromium (VI) trioxide 乙醚 、 水 、 碳酸氢钠 、 氯化钠 、 Sodium sulfate-III 作用下， 以 水 为溶剂， 反应 16.0h， 生成 3-(2-Benzoyl-4-chlorophenyl)prop-2-enenitrile
  参考文献：
  名称：

  Pyrrolo[3,4-d][2]benzazepinones

  摘要：

  本发明涉及以下式的化合物：##STR1##其中R.sub.1和R.sub.3选自氢、低烷基、羟基、低烷氧基或酰氧基的群组，R.sub.2和R.sub.4为氢或R.sub.1和R.sub.2和/或R.sub.3和R.sub.4一起取氧代基，但至少存在一个氧代基；R选自氢、低烷基、C.sub.2到C.sub.7羧酸及其酯和酰胺、羟基C.sub.2到C.sub.7烷基和氨基C.sub.2到C.sub.7烷基或单或双低烷基氨基C.sub.2到C.sub.7烷基；R.sub.5为卤素或氢；R.sub.6为卤素，但当R.sub.1或R.sub.3为羟基、低烷氧基或酰氧基时，R为低烷基或氢，以及其N-氧化物和药学上可接受的盐。

  公开号：

  US04436662A1
• 作为产物：
  描述：

  sodium;hydride 、 、 2-苄基-4-氯苯甲醛 在 四氢呋喃 、 水 、 乙醚 、 Sodium sulfate-III 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 3-(2-Benzyl-4-chlorophenyl)prop-2-enenitrile
  参考文献：
  名称：

  4-(2-Benzoylphenyl-1-pyazole and 4-(2-benzoylphenyl)-1-pyrazoline

  摘要：

  提供了以下化合物的结构式：其中R.sub.1是氢或较低的烷基；R.sub.6是卤素，R.sub.5是氢或卤素；以及以下结构式的化合物：其中R.sub.2和R.sub.3选自羟基较低的烷基，C.sub.2到C.sub.7羧酸，C.sub.2到C.sub.7羧酸酯和酰胺以及COR.sub.11，其中R.sub.11选自烷氧基，氨基或单烷基氨基；R.sub.35是氢或较低的烷基；R.sub.5是氢或卤素；R.sub.7是甲基或氯甲基。这些化合物在吡唑苯并噻唑的制备中有用。

  公开号：

  US04460781A1

文献信息

• Pyrazolobenzazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04379765A1

  公开（公告）日：1983-04-12

  There are presented compounds of the formulas ##STR1## wherein R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.3 are selected from the group consisting of hydrogen, lower alkyl, C.sub.2 to C.sub.7 carboxylic acids, hydroxy C.sub.2 to C.sub.7 alkyl, C.sub.2 to C.sub.7 carboxylic acid esters and amides and the group COR.sub.11 wherein R.sub.11 is alkoxy, amino or mono- lower alkyl amino; R.sub.6 is nitro or halo and R.sub.5 is hydrogen or halo, and the pharmaceutically acceptable salts thereof. The pyrazolobenzazepines are useful as anxiolytic and sedative agents. Also provided are processes and intermediates in the production of the above pyrazolobenzazepines.

  提供了以下公式的化合物：##STR1## 其中R.sub.1是氢或较低的烷基；R.sub.2和R.sub.3选自由氢、较低的烷基、C.sub.2到C.sub.7羧酸、羟基C.sub.2到C.sub.7烷基、C.sub.2到C.sub.7羧酸酯和酰胺以及COR.sub.11组，其中R.sub.11是烷氧基、氨基或单一低烷基氨基；R.sub.6是硝基或卤素，R.sub.5是氢或卤素，以及其药学上可接受的盐。这些吡唑苯并噁唑类化合物可用作抗焦虑和镇静剂。还提供了上述吡唑苯并噁唑类化合物的生产过程和中间体。
• Pyrrolo[3,4-d] [2] benzazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04405518A1

  公开（公告）日：1983-09-20

  The present invention relates to compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, hydroxymethyl, the group ##STR2## wherein R.sub.11 is hydrogen, hydroxy, alkoxy, amino and mono- or di-lower alkylamino; and R.sub.3 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, hydroxymethyl, the group ##STR3## wherein R.sub.11 is hydrogen, hydroxy, trihalomethyl, alkoxy, amino and mono- or di-lower alkylamino; R.sub.2 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, the group ##STR4## C.sub.2 to C.sub.7 carboxylic acids and the esters and amides thereof, hydroxy C.sub.2 to C.sub.7 alkyl and amino or mono- or di-lower alkyl amino C.sub.2 to C.sub.7 alkyl; R.sub.4 is selected from the group consisting of hydrogen, acyloxy, straight chain lower alkoxy and hydroxy; R.sub.5 is halogen or hydrogen; R.sub.6 is halogen with the proviso that if one of R.sub.1 or R.sub.3 is hydroxymethyl or the group - ##STR5## wherein R.sub.11 is as above then the remaining substituent is selected from the group consisting of hydrogen, lower alkyl and C.sub.3 to C.sub.7 alkenyl or alkynyl, and R.sub.2 is hydrogen and the further proviso that (A) when R.sub.4 is acyloxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and R.sub.2 is the group ##STR6## (B) when R.sub.4 is hydroxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and R.sub.2 is hydrogen or (C) when R.sub.4 is alkoxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and the pharmaceutically acceptable salts thereof. Also disclosed are certain 5,6 dihydro derivatives, N-oxides and quarternary iminium salts of the pyrrolobenzazepines.

  本发明涉及式为##STR1##的化合物，其中R.sub.1选择自羟基甲基，氢，低碳基，C.sub.3到C.sub.7烯基或炔基，羟甲基，##STR2##其中R.sub.11为氢，羟基，烷氧基，氨基和单或双低碳基氨基;和R.sub.3选择自氢，低碳基，C.sub.3到C.sub.7烯基或炔基，羟甲基，##STR3##其中R.sub.11为氢，羟基，三卤甲基，烷氧基，氨基和单或双低碳基氨基; R.sub.2选择自氢，低碳基，C.sub.3到C.sub.7烯基或炔基，##STR4##C.sub.2到C.sub.7羧酸及其酯和酰胺，羟基C.sub.2到C.sub.7烷基和C.sub.2到C.sub.7烷基的氨基或单或双低碳基氨基; R.sub.4选择自氢，酰氧基，直链低碳基烷氧基和羟基; R.sub.5选择自卤素或氢; R.sub.6选择自卤素，但如果R.sub.1或R.sub.3之一是羟甲基或-##STR5##其中R.sub.11如上所述，则其余取代基选择自氢，低碳基和C.sub.3到C.sub.7烯基或炔基，并且R.sub.2为氢，并且进一步规定当R.sub.4为酰氧基时，R.sub.1和R.sub.3为氢，低碳基，C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，而R.sub.2为##STR6##当R.sub.4为羟基时，R.sub.1和R.sub.3为氢，低碳基，C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，而R.sub.2为氢或当R.sub.4为烷氧基时，R.sub.1和R.sub.3为氢，低碳基，C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，以及其药学上可接受的盐。此外，还披露了某些吡咯并苯并氮杂环的5,6-二氢衍生物，N-氧化物和季铵盐。
• Pyrrolo[3,4-D][2]Benzazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04409390A1

  公开（公告）日：1983-10-11

  The present invention relates to compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, hydroxymethyl, the group ##STR2## wherein R.sub.11 is hydrogen, hydroxy, alkoxy, amino and mono- or di-lower alkylamino; and R.sub.3 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, hydroxymethyl, the group ##STR3## wherein R.sub.11 is hydrogen, hydroxy, trihalomethyl, alkoxy, amino and mono- or di-lower alkylamino; R.sub.2 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, the group ##STR4## C.sub.2 to C.sub.7 carboxylic acids and the esters and amides thereof, hydroxy C.sub.2 to C.sub.7 alkyl and amino or mono- or di-lower alkyl amino C.sub.2 to C.sub.7 alkyl; R.sub.4 is selected from the group consisting of hydrogen, acyloxy, straight chain lower alkoxy and hydroxy; R.sub.5 is halogen or hydrogen; R.sub.6 is halogen with the proviso that if one of R.sub.1 or R.sub.3 is hydroxymethyl or the group ##STR5## wherein R.sub.11 is as above then the remaining substituent is selected from the group consisting of hydrogen, lower alkyl and C.sub.3 to C.sub.7 alkenyl or alkynyl, and R.sub.2 is hydrogen and the further proviso that (A) when R.sub.4 is acyloxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and R.sub.2 is the group ##STR6## (B) when R.sub.4 is hydroxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and R.sub.2 is hydrogen or (C) when R.sub.4 is alkoxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and the pharmaceutically acceptable salts thereof. Also disclosed are certain 5,6 dihydro derivatives, N-oxides and quarternary iminium salts of the pyrrolobenzazepines.

  本发明涉及以下式的化合物：##STR1##其中R.sub.1从下列组中选择：氢、低碳基、C.sub.3到C.sub.7烯基或炔基、羟甲基、##STR2##其中R.sub.11为氢、羟基、烷氧基、氨基和单-或双-低碳基氨基；R.sub.3从下列组中选择：氢、低碳基、C.sub.3到C.sub.7烯基或炔基、羟甲基、##STR3##其中R.sub.11为氢、羟基、三卤甲基、烷氧基、氨基和单-或双-低碳基氨基；R.sub.2从下列组中选择：氢、低碳基、C.sub.3到C.sub.7烯基或炔基、##STR4##C.sub.2到C.sub.7羧酸及其酯和酰胺、羟基C.sub.2到C.sub.7烷基和氨基或单-或双-低碳基氨基C.sub.2到C.sub.7烷基；R.sub.4从下列组中选择：氢、酰氧基、直链低碳基氧基和羟基；R.sub.5为卤素或氢；R.sub.6为卤素，但如果R.sub.1或R.sub.3中的一个是羟甲基或##STR5##其中R.sub.11如上所述，则剩余的取代基从以下组中选择：氢、低碳基和C.sub.3到C.sub.7烯基或炔基，且R.sub.2为氢；进一步规定，当R.sub.4为酰氧基时，R.sub.1和R.sub.3为氢、低碳基、C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，R.sub.2为##STR6##当R.sub.4为羟基时，R.sub.1和R.sub.3为氢、低碳基、C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，R.sub.2为氢或当R.sub.4为烷氧基时，R.sub.1和R.sub.3为氢、低碳基、C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，以及其药学上可接受的盐。此外，本发明还公开了某些吡咯苯并莫匹啶的5,6-二氢衍生物、N-氧化物和季铵盐。
• Pyrrolo[3,4-d][2]benzazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04428878A1

  公开（公告）日：1984-01-31

  The present invention relates to compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, hydroxymethyl, the group ##STR2## wherein R.sub.11 is hydrogen, hydroxy, alkoxy, amino and mono- or di-lower alkylamino; and R.sub.3 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, hydroxymethyl, the group ##STR3## wherein R.sub.11 is hydrogen, hydroxy, trihalomethyl, alkoxy, amino and mono- or di-lower alkylamino; R.sub.2 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, the group ##STR4## C.sub.2 to C.sub.7 carboxylic acids and the esters and amides thereof, hydroxy C.sub.2 to C.sub.7 alkyl and amino or mono- or di-lower alkyl amino C.sub.2 to C.sub.7 alkyl; R.sub.4 is selected from the group consisting of hydrogen, acyloxy, straight chain lower alkoxy and hydroxy; R.sub.5 is halogen or hydrogen; R.sub.6 is halogen with the proviso that if one of R.sub.1 or R.sub.3 is hydroxymethyl or the group ##STR5## wherein R.sub.11 is as above then the remaining substituent is selected from the group consisting of hydrogen, lower alkyl and C.sub.3 to C.sub.7 alkenyl or alkynyl, and R.sub.2 is hydrogen and the further proviso that (A) when R.sub.4 is acyloxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and R.sub.2 is the group ##STR6## (B) when R.sub.4 is hydroxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and R.sub.2 is hydrogen or (C) when R.sub.4 is alkoxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and the pharmaceutically acceptable salts thereof which exhibit activity as sedatives and anxiolytics. Also disclosed are certain 5,6 dihydro derivatives, N-oxides and quarternary iminium salts of the pyrrolobenzazepines.

  本发明涉及以下式子的化合物：##STR1##其中R.sub.1选自羟基甲基、氢、低碳基、C.sub.3到C.sub.7烯基或炔基、##STR2##其中R.sub.11为氢、羟基、烷氧基、氨基和单或双低碳基氨基；R.sub.3选自氢、低碳基、C.sub.3到C.sub.7烯基或炔基、羟基甲基、##STR3##其中R.sub.11为氢、羟基、三卤甲基、烷氧基、氨基和单或双低碳基氨基；R.sub.2选自氢、低碳基、C.sub.3到C.sub.7烯基或炔基、##STR4##C.sub.2到C.sub.7羧酸及其酯和酰胺、羟基C.sub.2到C.sub.7烷基和氨基或单或双低碳基氨基C.sub.2到C.sub.7烷基；R.sub.4选自氢、酰氧、直链低烷氧基和羟基；R.sub.5为卤素或氢；R.sub.6为卤素，但如果R.sub.1或R.sub.3中有一个为羟基甲基或##STR5##其中R.sub.11如上所述，则其余取代基选自氢、低碳基和C.sub.3到C.sub.7烯基或炔基，且R.sub.2为氢，进一步规定当R.sub.4为酰氧时，R.sub.1和R.sub.3为氢、低碳基、C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，R.sub.2为##STR6##当R.sub.4为羟基时，R.sub.1和R.sub.3为氢、低碳基、C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，R.sub.2为氢或当R.sub.4为烷氧基时，R.sub.1和R.sub.3为氢、低碳基、C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，以及表现为镇静剂和抗焦虑剂的药物可接受的盐。此外，还披露了某些咪唑苯并螺环化合物的5,6-二氢衍生物、N-氧化物和季铵盐。
• Pyrrolo[3,4,-d][2]benzazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04428879A1

  公开（公告）日：1984-01-31

  The present invention relates to compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, hydroxymethyl, the group ##STR2## wherein R.sub.11 is hydrogen, hydroxy, alkoxy, amino and mono- or di-lower alkylamino; and R.sub.3 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, hydroxymethyl, the group ##STR3## wherein R.sub.11 is hydrogen, hydroxy, trihalomethyl, alkoxy, amino and mono- or di-lower alkylamino; R.sub.2 is selected from the group consisting of hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or alkynyl, the group ##STR4## C.sub.2 to C.sub.7 carboxylic acids and the esters and amides thereof, hydroxy C.sub.2 to C.sub.7 alkyl and amino or mono- or di- lower alkyl amino C.sub.2 to C.sub.7 alkyl; R.sub.4 is selected from the group consisting of hydrogen , acyloxy, straight chain lower alkoxy and hydroxy; R.sub.5 is halogen or hydrogen; R.sub.6 is halogen with the proviso that if one of R.sub.1 or R.sub.3 is hydroxymethyl or the group ##STR5## wherein R.sub.11 is as above then the remaining substituent is selected from the group consisting of hydrogen, lower alkyl and C.sub.3 to C.sub.7 alkenyl or alkynyl, and R.sub.2 is hydrogen and the further proviso that (A) when R.sub.4 is acyloxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and R.sub.2 is the group ##STR6## (B) when R.sub.4 is hydroxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and R.sub.2 is hydrogen or (C) when R.sub.4 is alkoxy then R.sub.1 and R.sub.3 are hydrogen, lower alkyl, C.sub.3 to C.sub.7 alkenyl or C.sub.3 to C.sub.7 alkynyl, and the pharmaceutically acceptable salts thereof which exhibit activity as sedatives and anxiolytics. Also disclosed are certain 5,6 dihydro derivatives, N-oxides and quarternary iminium salts of the pyrrolobenzazepines.

  本发明涉及以下式的化合物：##STR1##其中R.sub.1选自由氢、较低烷基、C.sub.3到C.sub.7烯基或炔基、羟甲基、##STR2##其中R.sub.11为氢、羟基、烷氧基、氨基和单-或双-较低烷基氨基；R.sub.3选自由氢、较低烷基、C.sub.3到C.sub.7烯基或炔基、羟甲基、##STR3##其中R.sub.11为氢、羟基、三卤甲基、烷氧基、氨基和单-或双-较低烷基氨基；R.sub.2选自由氢、较低烷基、C.sub.3到C.sub.7烯基或炔基、##STR4##C.sub.2到C.sub.7羧酸及其酯和酰胺、羟基C.sub.2到C.sub.7烷基和C.sub.2到C.sub.7烷基的氨基或单-或双-较低烷基氨基；R.sub.4选自由氢、酰氧基、直链较低烷氧基和羟基；R.sub.5为卤素或氢；R.sub.6为卤素，但前提是如果R.sub.1或R.sub.3中的一个是羟甲基或##STR5##其中R.sub.11如上所述，那么剩余的取代基选自由氢、较低烷基和C.sub.3到C.sub.7烯基或炔基，而R.sub.2为氢，进一步前提是(A)当R.sub.4为酰氧基时，R.sub.1和R.sub.3为氢、较低烷基、C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，而R.sub.2为##STR6##(B)当R.sub.4为羟基时，R.sub.1和R.sub.3为氢、较低烷基、C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，而R.sub.2为氢或(C)当R.sub.4为烷氧基时，R.sub.1和R.sub.3为氢、较低烷基、C.sub.3到C.sub.7烯基或C.sub.3到C.sub.7炔基，以及具有镇静和抗焦虑活性的药物可接受的盐。还公开了某些吡咯并苯并螺氮平的5,6-二氢衍生物、N-氧化物和季铵盐。